ライフサイエンスコーパス: vaccinia

1 sion in promoting the cell-to-cell spread of vaccinia.

2 however, reduces the cell-to-cell spread of vaccinia.

3 Emerging evidence from vaccinia and influenza A virus infections indicates that

4 Among these candidates are vaccinia and myxoma viruses, which belong to the family

5 ion and generation of specific peptides from vaccinia- and influenza A virus-encoded proteins.

6 : replication-deficient adenovirus; modified vaccinia Ankara (a poxvirus); protein with alum; and pro

7 veral months, we boosted ChAd3 with modified vaccinia Ankara (MVA) and generated, for the first time,

8 en of peptide priming followed by a modified vaccinia Ankara (MVA) boost in a nonhuman primate model,

9 denovirus serotype 26 (Ad26) prime, modified vaccinia Ankara (MVA) boost) and stimulation of TLR7 (To

10 old range of an admixed recombinant modified vaccinia Ankara (MVA) expressing rhesus GM-CSF (MVA/GM-C

11 Attenuated poxvirus modified vaccinia Ankara (MVA) is a useful viral-based vaccine fo

12 of lactating rhesus monkeys with a modified vaccinia Ankara (MVA) prime/intramuscular (i.m.) protein

13 ffect of adding a booster dose of a modified vaccinia Ankara (MVA) strain, encoding the same Ebola vi

14 Clade B DNA and recombinant modified vaccinia Ankara (MVA) vaccines producing virus-like part

15 tein from a clinically proven safe, Modified Vaccinia Ankara (MVA) vector, thus averting the potentia

16 TG4040 is a modified vaccinia Ankara (MVA) virus that expresses the hepatitis

17 Modified vaccinia Ankara (MVA-BN, IMVAMUNE) is emerging as a prim

18 TG4010 is a modified vaccinia Ankara expressing MUC1 and interleukin 2.

19 effect of boosting of Malians with modified vaccinia Ankara expressing Zaire Ebola virus glycoprotei

20 enhanced, T and B cell responses to modified vaccinia Ankara vaccination in a nonhuman primate model

21 using PBMCs isolated on day 7 post-modified vaccinia Ankara vaccination, the earliest time point at

22 B cell and Ab responses induced by modified vaccinia Ankara were extremely weak.

23 Preliminary data using modified vaccinia Ankara-5T4 (MVA-5T4) in mCRC demonstrated that

24 enicity evaluation of PENNVAX-G DNA/modified vaccinia Ankara-Chiang Mai double recombinant (MVA-CMDR)

25 After an i.m. modified vaccinia Ankara/Gag boost, we observed robust Gag-specif

26 A recombinant vaccinia-based method for expressing uptake transporters

27 We have reported that a vaccinia-based OV (Pexa-Vec) has shown good efficacy in

28 human somatostatin receptor 2 (hSSR2) in the vaccinia-based OV and tested viral constructs for their

29 , Sindbis, vesicular stomatitis, cowpox, and vaccinia, but not murine leukemia or adenovirus.

30 nhibits intravenously administered oncolytic vaccinia delivery to and consequent spread within the tu

31 trated that many envelope viruses, including vaccinia, dengue, West Nile, and Ebola viruses, utilize

32 fluorescent nanodiamonds (FNDs) coated with vaccinia envelope proteins as the model system.

33 T cell responses or improve protection from vaccinia-Gag challenge.

34 protection (i.e., sterilizing immunity) from vaccinia-Gag challenge.

35 vaccine-induced protection from challenge by vaccinia-Gag virus.

36 Vaccinia H1-related phosphatase (VHR/DUSP3) is a member

37 Our observations with vaccinia have now demonstrated that RhoD recruits Pak6 t

38 logous prime-boost regimens, with a New York vaccinia HIV clade B (NYVAC-B) vaccine and a recombinant

39 Vaccinia immune globulin (VIG) has been used therapeutic

40 Similarly, hSSR2-containing OV vaccinia infected and lysed cancer cells.

41 e further characterize the role of B1 during vaccinia infection to gain novel insights into its regul

42 vealed that PP2A dephosphorylates BAF during vaccinia infection, thus counterbalancing the activity o

43 previously identified a nonsense mutation in Vaccinia-related kinase 1 (VRK1), R358X, as a cause of S

44 Vaccinia-related kinase 1 is the major kinase responsibl

45 Vaccinia-related kinase 2 (VRK2) is known to negatively

46 These studies identify vaccinia-related kinase-2 (VRK2) as a candidate constitu

47 The human genome encodes two active Vaccinia-related protein kinases (VRK), VRK1 and VRK2.

48 Vaccinia still induces actin tails in the absence of the

49 The vaccinia viral protein A27 in mature viruses specificall

50 haped tubular structure in the center of the vaccinia virion core.

51 The vaccinia virion structural protein L4 stands out as the

52 ance to immunotherapies, including oncolytic vaccinia virotherapy.

53 ed interactions between genetically-modified vaccinia virus (GLV-1h68) and radiotherapy in melanoma c

54 ract of inflamed rabbit skin inoculated with vaccinia virus (Neurotropin((R))) enhanced efficiency of

55 of a CXCR4 antagonist expressed by oncolytic vaccinia virus (OVV) against an invasive variant of the

56 adults, with or without immunity to CMV and vaccinia virus (previous DryVax smallpox vaccination).

57 owed by intranasal boosting with recombinant vaccinia virus (rVV) encoding S436 or S525 resulted in a

58 Vaccinia virus (VACV) A27 is a target for viral neutrali

59 In this study, we applied vaccinia virus (VACV) by scarification to IL-1R1 knockou

60 Vaccinia virus (VACV) continues to be used in immunother

61 produced in excess in cells infected with a vaccinia virus (VACV) decapping enzyme mutant and by wil

62 Vaccinia virus (VACV) decapping enzymes and cellular exo

63 The vaccinia virus (VACV) E3 protein has been shown to be im

64 The I2L open reading frame of vaccinia virus (VACV) encodes a conserved 72-amino-acid

65 Vaccinia virus (VACV) encodes an innate immune evasion p

66 The poxvirus vaccinia virus (VACV) encodes numerous inhibitors of NF-

67 Vaccinia virus (VACV) encodes several proteins that inhi

68 Vaccinia virus (VacV) encodes two decapping enzymes (D9,

69 Vaccinia virus (VACV) envelope protein D8 is one of thre

70 This work reveals the prototypic poxvirus Vaccinia virus (VACV) exploits cellular retrograde trans

71 ses; instead, we identified mutations in two vaccinia virus (VACV) genes, A24R and A35R, either of wh

72 have determined the crystal structure of the vaccinia virus (VACV) H7 protein.

73 assessed several routes of immunization with vaccinia virus (VACV) in protecting mice against ectrome

74 This study investigates how vaccinia virus (VACV) infection alters global cellular m

75 -knockout CD8(+) TRM cells generated by skin vaccinia virus (VACV) infection were less effective at p

76 In establishing a respiratory infection, vaccinia virus (VACV) initially replicates in airway epi

77 Vaccinia virus (VACV) is a member of the Poxviridae fami

78 Vaccinia virus (VACV) is a poxvirus, and the VACV D4 pro

79 Vaccinia virus (VACV) is a useful model system for under

80 Skin scarification (s.s.) with vaccinia virus (VACV) is essential for generation of an

81 The vaccinia virus (VACV) K1 protein has multiple immunomodu

82 elicited protective immunity.IMPORTANCE The vaccinia virus (VACV) K1 protein inhibits NF-kappaB acti

83 Vaccinia virus (VACV) keratitis is a serious complicatio

84 Vaccinia virus (VACV) L1 is an important target for vira

85 The vaccinia virus (VACV) M1 ankyrin (ANK) protein, a protei

86 f a novel apoptosis inhibitor encoded by the vaccinia virus (VACV) M1L gene.

87 Vaccinia virus (VACV) provides the backbone for some of

88 Successful vaccinia virus (VACV) replication in the host requires e

89 PKRs were able to restrict replication of a vaccinia virus (VACV) strain that lacks the PKR inhibito

90 high-throughput RNAi screen directed against vaccinia virus (VACV) to identify the VACV AAA+ ATPase D

91 Poxviruses such as Vaccinia virus (VACV) undertake a complex cytoplasmic re

92 The 50% lethal intraperitoneal dose of vaccinia virus (VACV) was 3 PFU for CAST mice, whereas B

93 virus (ECTV), a natural mouse pathogen, and vaccinia virus (VACV), a heterologous virus that neverth

94 arly every step in the reproductive cycle of vaccinia virus (VACV), a large DNA virus with about 200

95 is overcome when cells are co-infected with vaccinia virus (VACV), a vertebrate DNA virus.

96 y plasmid can replicate in cells infected by vaccinia virus (VACV), the prototype poxvirus.

97 n of proteins on nascent DNA) to investigate vaccinia virus (VACV), the prototype poxvirus.

98 Yet, in the case of vaccinia virus (VACV), which constitutes the vaccine use

99 We used vaccinia virus (VACV)--a gold standard vaccine--as the i

100 Using skin infections with vaccinia virus (VacV)-expressing model antigens, we foun

101 are antigen-transporting cells that generate vaccinia virus (VACV)-specific T-cell responses, yet how

102 ient (nude, nu/nu) BALB/c mice infected with vaccinia virus (VACV).

103 EdU) into nascent DNA in cells infected with vaccinia virus (VACV).

104 e immunity to a number of viruses, including vaccinia virus (VACV).

105 in the replication of the prototype poxvirus vaccinia virus (VACV).

106 lymphocytic choriomeningitis virus (LCMV) or vaccinia virus (VACV).

107 ted only to exhibit abortive infections with vaccinia virus (VACV).

108 ancer-killing (oncolytic) virus therapy with vaccinia virus (VACV).

109 evealed new insights into the endocytosis of vaccinia virus (VACV).

110 ed among poxviruses, including A6 and A11 of vaccinia virus (VACV).

111 ccination program using different strains of vaccinia virus (VACV; Poxviridae).

112 We determined that a K1L-less vaccinia virus (vDeltaK1L) was less pathogenic than wild

113 e epidermis known as eczema vaccinatum after vaccinia virus (VV) infection of the skin.

114 Epicutaneous vaccinia virus (VV) infection, mimicking human smallpox

115 Chimpanzee adenovirus-6 (AdC6) or -7 (AdC7), Vaccinia virus (VV), and DNA given by electroporation (D

116 each viral protein in persons immunized with vaccinia virus (VV), either recently or more than 40 yea

117 The vaccinia virus A56 and K2 proteins in the cell membrane

118 In this study, we uncovered a means of vaccinia virus adaptation involving the accumulation of

119 e-prototype JX-594), a replication-competent vaccinia virus administered by intravenous injection, to

120 steria monocytogenes, Shigella flexneri, and Vaccinia virus among other pathogens use the same common

121 It is not enriched for vaccinia virus and Candida albicans-MP65 (immunodominant

122 oping potent neutralizing antibodies against vaccinia virus and comprehensively characterizing their

123 e membrane-wrapping step in morphogenesis of vaccinia virus and egress from the cell.

124 panied by increased viral resistance against vaccinia virus and influenza B virus infections.

125 res are also induced by two other pathogens (vaccinia virus and Listeria monocytogenes).

126 its actin polymerization downstream of EPEC, Vaccinia virus and opsonized red blood cells.

127 Efficient cell-to-cell spread of vaccinia virus and other orthopoxviruses depends on the

128 bisbenzimide derivatives are potent against vaccinia virus and other poxviruses but ineffective agai

129 Vaccinia virus and other poxviruses encode enzymes for b

130 bility to monkeypox virus, cowpox virus, and vaccinia virus and thus providing a unique model for stu

131 r of the Orthopoxvirus genus, which includes Vaccinia virus and Variola virus (the causative agent of

132 rus is intermediate in pathogenicity between vaccinia virus and variola virus.

133 uential immunizations with DNA (D), modified vaccinia virus Ankara (MVA) (M), and protein immunogens,

134 The clinically relevant vectors modified vaccinia virus Ankara (MVA) and the chimpanzee adenoviru

135 impanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) and used to immunize mice in

136 Using a modified vaccinia virus Ankara (MVA) as a vaccine model, we chara

137 A DNA prime-modified vaccinia virus Ankara (MVA) boost vaccine has proven to

138 priming with DNA and boosting with modified vaccinia virus Ankara (MVA) expressing HIV-1 Env on viru

139 Modified vaccinia virus Ankara (MVA) is a safe and well-character

140 asal administration of the poxvirus modified vaccinia virus Ankara (MVA) is sufficient to induce high

141 ctors simian adenovirus 63 (ChAd63)-modified vaccinia virus Ankara (MVA) is the most potent inducer o

142 we show that a CD40L-adjuvanted DNA/modified vaccinia virus Ankara (MVA) simian immunodeficiency viru

143 M1L is absent in the attenuated modified vaccinia virus Ankara (MVA) strain of VACV, a strain tha

144 We have constructed a recombinant modified vaccinia virus Ankara (MVA) that expresses an H5N1 mosai

145 to adjuvant the DNA prime of a DNA/modified vaccinia virus Ankara (MVA) vaccine in rhesus macaques.

146 ity to both insert Ag85A and vector modified vaccinia virus Ankara (MVA) was assessed by ex-vivo inte

147 The poxvirus strain modified vaccinia virus Ankara (MVA), a safe and efficient viral

148 ific T cells induced by a DNA-prime modified vaccinia virus Ankara (MVA)-boost vaccination strategy,

149 virus (SIV) challenges in seven DNA/modified vaccinia virus Ankara (MVA)-vaccinated rhesus macaques w

150 onserved antigenic regions by using modified vaccinia virus Ankara (MVA).

151 sized and cloned into a recombinant modified vaccinia virus Ankara (MVA).

152 /IL-15, SIV Gag/Pol/Env recombinant modified vaccinia virus Ankara (rMVA), and AT-2 SIVmac239 inactiv

153 imate model that vaccination with a modified vaccinia virus Ankara encoding hemagglutinin from a hete

154 f a candidate tuberculosis vaccine, modified vaccinia virus Ankara expressing antigen 85A (MVA85A), i

155 We show that booster modified vaccinia virus Ankara immunization induced a distinct an

156 e questions in the context of a DNA/modified vaccinia virus Ankara SIV vaccine with and without gp140

157 r SIVmac239 envelope-expressing DNA/modified vaccinia virus Ankara vector- and protein-based vaccinat

158 oost regimen with a mixture of MVA (Modified Vaccinia virus Ankara) and Ad5 (human adenovirus type 5)

159 far, well-described vectors such as modified vaccinia virus Ankara, complex adenovirus, vesicular sto

160 impanzee adenovirus 63, ChAd63, and modified vaccinia virus Ankara, MVA, expressing AgAPN1, Pfs230-C,

161 ized with SIVmac239-based DNA-prime/modified vaccinia virus Ankara-boost vaccine regimens that includ

162 ther a chimpanzee adenovirus 63 and modified vaccinia virus Ankara-vectored vaccine expressing a mult

163 second homologous immunization with modified vaccinia virus Ankara.

164 as been developed using the immunogenic live vaccinia virus as a vaccine vector, expressing multiple

165 protein toxins, potently prevented spread of vaccinia virus as well as monkeypox virus, a human patho

166 we present the crystal structure of H3 from vaccinia virus at a 1.9-A resolution.

167 and ovarian cancer models that an oncolytic vaccinia virus attracts effector T cells and induces PD-

168 t that dynamic phosphorylation involving the vaccinia virus B1 kinase and cellular enzymes is likely

169 The vaccinia virus B1 kinase is highly conserved among poxvi

170 The most well characterized role for the vaccinia virus B1 kinase is to facilitate viral DNA repl

171 The vaccinia virus B1 protein is a homolog of cellular vacci

172 HIV-1 antigens, with one of them lacking the vaccinia virus B19 protein, an inhibitor of the type I i

173 The vaccinia virus B1R gene encodes a highly conserved prote

174 Although superinfecting vaccinia virus bound to cells, infection was inhibited a

175 uperinfection exclusion may be beneficial to vaccinia virus by selecting particles that can infect ce

176 host-range proteins that share homology with vaccinia virus C7 protein.

177 red improved protection against Listeria and vaccinia virus challenges compared with the Armstrong bo

178 Thus, vDeltaK1L is the first vaccinia virus construct reported that caused a muted in

179 ispensable for determining the mechanisms of vaccinia virus core-directed transcription.

180 Thus, vaccinia virus decapping, in addition to targeting mRNAs

181 nsight into the role of D4 as a co-factor of vaccinia virus DNA polymerase and allows a better unders

182 Vaccinia virus early genes are transcribed immediately u

183 Because vaccinia virus early transcription is coupled to the vir

184 EPD of vaccinia virus encoding OVA induced significantly higher

185 gainst intranasal challenge with recombinant vaccinia virus encoding p24.

186 Comparison of responses to vaccinia virus expressing OVA peptide SIINFEKL by wild-t

187 vides complete immune control of recombinant vaccinia virus expressing the same epitope if KCSRNRQYL

188 CD8(+) T cells act synergistically to clear vaccinia virus from a primary skin infection.

189 ed RNA start sites have made the analysis of vaccinia virus gene expression challenging.

190 rhtrs1-amplified viruses, there arose in two vaccinia virus genes mutations that improved viral repli

191 t on the rapid positive selection of a novel vaccinia virus genomic duplication mutant in the presenc

192 omologs of the Bcl-2 family of proteins, and vaccinia virus harbors antiapoptotic F1L that potently i

193 The smallpox vaccine using vaccinia virus has been highly successful, but it is sti

194 modified by the insertion of the K1L and C7L vaccinia virus host range genes and express the clade C(

195 per by applying it to SIM and STED images of vaccinia virus in isolation and when engaged with host c

196 , we analyzed the responses of host cells to vaccinia virus infection at both the transcriptional and

197 minor groove of double-stranded DNA, inhibit vaccinia virus infection by blocking viral DNA replicati

198 This study highlights the fact that vaccinia virus infection can enhance cellular energy pro

199 Vaccinia virus infection causes a host shutoff that is m

200 Using a model of respiratory vaccinia virus infection in mice, we could specifically

201 In this study, with vaccinia virus infection in mice, we show that OX40 was

202 dependent of infection or during a surrogate vaccinia virus infection to identify how MC159 prevented

203 infection with either virus, after a cleared vaccinia virus infection, and during a persistent/latent

204 f oxidative phosphorylation increased during vaccinia virus infection, while inhibition of the cellul

205 regulation of the CD8(+) T cell response to vaccinia virus infection.

206 ncreased and accelerated mortality following vaccinia virus infection.

207 most bone marrow T cells activate 3 d after vaccinia virus infection.

208 dly increase translation in the first day of vaccinia virus infection.

209 LECs toward MPECs, during the acute phase of vaccinia virus infection.

210 ty to localize infected cells and to control vaccinia virus infection.

211 which accelerates clearance of epicutaneous vaccinia virus infection.

212 e ability to act as a potent defense against vaccinia virus infection.

213 cific CD8(+) T cells responses to subsequent vaccinia virus infection.

214 mune detection pathways, we performed serial vaccinia virus infections in primary human cells.

215 Vaccinia virus is a powerful model to study antibody res

216 nd vaccination of patients with AD with live vaccinia virus is contraindicated because of a heightene

217 present evidence that the impact of VRK2 on vaccinia virus is largely independent of BAF phosphoryla

218 Until now, all known rifampin-resistant vaccinia virus isolates have contained missense mutation

219 On the basis of these results, vaccinia virus keratitis is significantly different from

220 We found a site in vaccinia virus L1 protein as the target of a group of hi

221 nd D10, but not of either enzyme alone, halt vaccinia virus late protein synthesis and inhibit virus

222 that B1 is required at another stage of the vaccinia virus life cycle.

223 Thus, vaccinia virus makes novel use of the retrograde transpo

224 sion in other viral systems, did not prevent vaccinia virus membrane fusion, suggesting that these in

225 revealed that this protein is essential for vaccinia virus morphogenesis and that its absence result

226 The vaccinia virus nucleocapsid has been neglected since the

227 of high-pressure freezing in preserving the vaccinia virus nucleocapsid.

228 We characterized a mouse model of vaccinia virus ocular disease using C57BL/6 mice and str

229 virions excluded hundreds of superinfecting vaccinia virus particles.

230 Vaccinia virus polymerase holoenzyme is composed of the

231 t rabbits immunized with a novel recombinant vaccinia virus prime-gp120 protein boost regimen generat

232 network is also assembled downstream of the Vaccinia virus protein A36 and the phagocytic Fc-gamma r

233 We now demonstrate that the vaccinia virus protein F11, which localizes to the plasm

234 Five conserved vaccinia virus proteins, referred to as Viral Membrane A

235 ide evidence for the phosphoglycosylation of vaccinia virus proteins.

236 n and luciferase reporters demonstrated that vaccinia virus recognized MOCV intermediate and late pro

237 depend on host cells to provide, to support vaccinia virus replication during a host shutoff.IMPORTA

238 iscovered that TRAF2 is a proviral factor in vaccinia virus replication in both HeLa cells and mouse

239 ver, Ripk1(D138N/D138N) mice fail to control vaccinia virus replication in vivo.

240 the beginning of the 1980s, research on the vaccinia virus replication mechanism has basically stall

241 maintenance of its function is important for vaccinia virus replication.

242 horylation function significantly suppressed vaccinia virus replication.

243 Vaccinia virus ribosome-associated mRNA sequences were d

244 Poxviruses, myxoma virus and vaccinia virus specifically, utilize a virus-encoded hos

245 ection of C57BL/6 mice with 1 x 10(7) PFU of vaccinia virus strain WR results in blepharitis, corneal

246 e B21/22 family glycoproteins not encoded by vaccinia virus strains used as vaccines.

247 In this study, we show across a range of vaccinia virus strains, including the current clonal sma

248 ved in isolates from an outbreak of zoonotic vaccinia virus that occurred in Brazil.

249 antiviral protein PKR, enabled a recombinant vaccinia virus to replicate in resistant cells from huma

250 here that this expanded tropism of oncolytic vaccinia virus to the endothelial compartment is a conse

251 During its egress, vaccinia virus transiently recruits AP-2 and clathrin af

252 uct a high-resolution genome-wide map of the vaccinia virus translatome.

253 deep study of the covalent structure of the vaccinia virus virion using the various tools of contemp

254 xamine the protein covalent structure of the vaccinia virus virion.

255 We report here that the engineered oncolytic vaccinia virus VVWR-TK(-)RR(-)-Fcu1 can induce immunogen

256 We showed that superinfection by vaccinia virus was prevented at the membrane fusion step

257 ll function in the lung after infection with vaccinia virus, a member of the Poxviridae family.

258 immune-deficient (nu/nu) mice infected with vaccinia virus, a model of smallpox.

259 at causes a persistent/latent infection, and vaccinia virus, a poxvirus that is cleared by the host.

260 es of fatty acid in the diet on infection by vaccinia virus, an acute infection that begins in the re

261 vo from mRNA synthesized in the cytoplasm by vaccinia virus, and hence cannot be spliced.

262 immunization with Plasmodium sporozoites or vaccinia virus, but a few weeks later their numbers seve

263 onocytogenes, vesicular stomatitis virus, or Vaccinia virus, but dispensable in the case of mouse cyt

264 gression are arrested in cells infected with vaccinia virus, but mass fluctuations continue until cel

265 n a murine model of cutaneous infection with vaccinia virus, dermal gammadelta T cell numbers increas

266 aa 21-84), a recombinant envelope protein of vaccinia virus, for glycosaminoglycans (GAGs)-specific t

267 fficacy of a replication-competent oncolytic vaccinia virus, GLV-1h153, carrying human sodium iodide

268 We demonstrated that a novel vaccinia virus, GLV-1h153, expresses hNIS, increases the

269 on, and in the case of influenza B virus and vaccinia virus, ISG15 conjugation has been shown to rest

270 Upon infections with Toxoplasma gondii and vaccinia virus, mice with stabilized DC beta-catenin dis

271 icited against allogeneic RhD+ erythrocytes, vaccinia virus, rotavirus, or tetanus toxoid provides ev

272 Vaccinia virus, the live vaccine for smallpox, is one of

273 When compared to vaccinia virus, this archival strain contained the same

274 e inhibitor 1 (SPI-1) of rabbitpox virus and vaccinia virus, two closely related orthopoxviruses, pre

275 From our work with vaccinia virus, we give first insights into the overall

276 ymphocytic choriomeningitis virus (LCMV) and vaccinia virus, where the pathogens are cleared, but it

277 sease is induced by intradermal injection of vaccinia virus, whereas a protective response occurs wit

278 TRAP is delivered using adenovirus- and vaccinia virus-based vectors in a prime-boost regime.

279 accination of rhesus monkeys compared to the vaccinia virus-based vectors MVA and NYVAC.

280 virion preparations, >88% of the theoretical vaccinia virus-encoded proteome was detected with high c

281 RNAs were translationally upregulated during vaccinia virus-induced host protein synthesis shutoff.

282 ured the host mRNA translation rate during a vaccinia virus-induced host shutoff by analyzing total a

283 ns may be selectively synthesized during the vaccinia virus-induced host shutoff.

284 ia virus B1 protein is a homolog of cellular vaccinia virus-related kinases (VRKs) and is needed for

285 xhibits a remarkable degree of similarity to vaccinia virus-related kinases (VRKs), a family of cellu

286 merous RNA viruses but enhances the entry of vaccinia virus.

287 ized against foreign rhesus D alloantigen or vaccinia virus.

288 the movement of microbial pathogens such as vaccinia virus.

289 athway components for cell-to-cell spread of vaccinia virus.

290 mory CD8(+) T cells following infection with vaccinia virus.

291 sing data from humans, domestic pigeons, and vaccinia virus.

292 the crystal structure of the H7 protein from vaccinia virus.

293 g during a severe respiratory infection with vaccinia virus.

294 and in vivo, during immune responses against vaccinia virus.

295 scent formation, including the A6 protein of vaccinia virus.

296 perator sequence) into oncolytic recombinant vaccinia viruses (rVACV), which were further characteriz

297 peptide-pulsed dendritic cells, recombinant vaccinia viruses encoding full-length T Ag or epitope mi

298 ges in the cytoskeleton, studies with mutant vaccinia viruses indicated that the cytoskeletal changes

299 res of the antitumor properties of oncolytic vaccinia viruses, all of which can be amplified by the m

300 uitment of leukocytes, which is unique among vaccinia viruses.